Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Debt: 2016-2024

Historic Non-Current Debt for Heron Therapeutics (HRTX) over the last 4 years, with Dec 2024 value amounting to $25.0 million.

  • Heron Therapeutics' Non-Current Debt rose 332.93% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 332.93%. This contributed to the annual value of $25.0 million for FY2024, which is 3.14% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Non-Current Debt is $25.0 million, which was up 3.14% from $24.3 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Non-Current Debt peaked at $25.0 million during FY2024, and registered a low of $24.3 million during FY2023.
  • Moreover, its 2-year median value for Non-Current Debt was $24.6 million (2023), whereas its average is $24.6 million.
  • Data for Heron Therapeutics' Non-Current Debt shows a peak YoY rose of 3.14% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Heron Therapeutics' Non-Current Debt stood at $24.3 million in 2023, then rose by 3.14% to $25.0 million in 2024.